The Next Frontier of Medicines for Cardioendocrine Diseases. Backed by Third Rock Ventures.
About the role
Reporting to the Director of Clinical Operations, the Senior Clinical Trial Manager (Sr. CTM) will lead the day-to-day execution and management of clinical trials, ensuring studies are conducted efficiently, on time, within budget, and in compliance with GCP and regulatory requirements.
What they're looking for
- Support program lead with setting and timely executing the development strategies for the clinical studies
- Responsible for the strategic and operational oversight, management, execution, and delivery of the clinical studies for MAR002 and related clinical program activities
- Lead the Study Management Team (SMT) for assigned clinical study
- Resolve and/or escalate issues raised by the clinical operations team or the SMT
- Ensure consistency between studies for assigned clinical program
- Support vendor selection, including request for proposals, leading bid defense meetings, critical review of contracts and negotiation of work orders
More about this role
Marea Therapeutics is a clinical-stage biotechnology company based in South San Francisco with a growing pipeline of first-in-class therapies to address genetically validated cardioendocrine disease targets. Our therapies have the potential to serve as transformative treatment options for significant patient populations living with cardioendocrine diseases.
The company’s lead program, MAR001, is being developed for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels and elevated risk of acute pancreatitis. Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. MAR001 has demonstrated strong and a differentiated profile in patients and is approaching Phase 3 development. Our second clinical asset, MAR002, is a monoclonal antibody targeting excess growth hormone produced by the pituitary gland in the rare hormonal disorder, acromegaly. MAR002 has potential to become best-in-disease and is quickly progressing into Phase 2/3 clinical development. We also have a third asset that is swiftly advancing through research discovery, with DC...
Browse similar: Startup jobs · San Francisco Bay Area